Raymond James Financial Services Advisors’s Gyre Therapeutics GYRE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,642	Closed	-$205K	–	3373
2021 Q3	$205K	Sell	6,642 -30	-0.4%	-$987	﹤0.01%	2968
2021 Q2	$217K	Sell	6,672 -6,866	-51%	-$236K	﹤0.01%	2956
2021 Q1	$512K	Buy	13,538 +2,906	+27%	+$133K	﹤0.01%	2269
2020 Q4	$503K	Buy	10,632 +5,306	+100%	+$230K	﹤0.01%	2141
2020 Q3	$172K	Sell	5,326 -233	-4%	-$9.12K	﹤0.01%	2582
2020 Q2	$245K	Buy	+5,559	New	+$261K	﹤0.01%	2364

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Raymond James Financial Services Advisors's GYRE Position: Q4 2021 in Review

Raymond James Financial Services Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 6,642 shares — an estimated $205K sold.

Raymond James Financial Services Advisors first reported a position in GYRE in Q2 2020 and held it in 6 quarters. The position peaked at $512K in Q1 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

Raymond James Financial Services Advisors reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
Raymond James Financial Services Advisors sold 6,642 Gyre Therapeutics shares in Q4 2021, an estimated $205K.
Raymond James Financial Services Advisors first reported a position in Gyre Therapeutics in Q2 2020 and held it in 6 quarters.
Raymond James Financial Services Advisors's Gyre Therapeutics position peaked at $512K in Q1 2021.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.